Clinical Trial Update: A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating HYML-122 plus Cytarabine in FLT3-positive relapsed or refractory AML; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• HYML-122

Snippet

Sponsor: Tarapeutics Science Inc. | Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Status: RECRUITING